Providing Access to Cord Blood Units for Transplants
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
This date has not been verified as actual or estimated.
Primary Completion
November 26, 2012
Actual (reported)
Study Completion
November 26, 2012
Actual (reported)
Brief Summary
Background: \- Cord blood banks have been set up to collect and store umbilical cord blood for transplants. These transplants are used to treat different types of cancer. In October 2011, the Food and Drug Administration (FDA) began considering cord blood as a biological drug. Most of the cord blood units currently available in cord blood banks in the United States and other countries were collected before the FDA set these new standards. The units meet standards set by the National Marrow Donor Program (NMDP), but they were not collected, tested, or stored exactly according to FDA standards. As a result, the new guidelines state that they may only be used for transplant if the transplant is done as part of a study. Researchers have set up a study to provide these cord blood units to recipients and to study the effects of their use. Objectives:
To provide access to cord blood units for recipients whose best choice for a unit meets NMDP but not FDA standards.
To study the effects of these cord blood transplants. Eligibility: \- Individuals who need to have a cord blood transplant to treat certain types of cancer. Design:
Participants will be screened with a physical exam, medical history. They will also have blood tests and imaging studies.
Participants will have the cord blood transplant and allow their medical data to be collected by the study researchers.
Registry Overview
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Recruitment status
withdrawn
Actual enrollment (reported)
0 participants
Study completion date
November 26, 2012
Actual (reported)
Listed locations
0 countries · 0 sites
Trial Relationships
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Related Scientific Literature
Loading related publications...
Study Timeline
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
Study Start
October 27, 2011
Date type not reported
This date has not been verified as actual or estimated.
Adult and PediatricUnlicensed Cord Blood Unit INDNMDPTransplantHematologic MalignanciesLeukemiaMultiple MyelomaNon-Hodgkin LymphomaCMLChronic Myelogenous LeukemiaMyelodyplastic SyndromeMDSThalassemiaLysosomal Storage Diseases
Outcome Measures
Primary Outcomes (1)
The primary aim of this study is to examine the incidence of neutrophil recovery of greater than or equal to 500/mm3 after cord blood transplantation in a multi-institution setting using CBUs that are not Food and Drug Administration (FDA) licen...
Secondary Outcomes (5)
Assess incidence of graft rejection.
Assess incidence of transmission of infection.
Assess incidence of serious infusion reaction.
Determine 1 year survival after cord blood transplantation.
Assess cumulative incidence of aGVHD vs cGVHD.
Interventions
Access to unlicensed cord blood unitsDrug
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Eligibility Criteria
AgeUp to 99 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, Gerson SL, Lazarus HM, Cairo M, Stevens CE, Rubinstein P, Kurtzberg J. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001 Jun 14;344(24):1815-22. doi: 10.1056/NEJM200106143442402.
Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocci G, Carrier C, Stevens CE, Rubinstein P. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996 Jul 18;335(3):157-66. doi: 10.1056/NEJM199607183350303.
Certain lysosomal storage and peroxisomal enzyme deficiency disorders
Hurler syndrome (MPS I)
Krabbe Disease (Globoid Leukodystrophy)
X-linked Adrenoleukodystrophy
Primary immunodeficiency diseases
Bone marrow failure
Beta-thalassemia
Signed informed consent (and signed assent, if applicable)
Pediatric and adult patients of any age
You may not qualify if:
Patients who are receiving only licensed CBUs
Cord blood transplant recipients at international transplant centers
Contact the study team to confirm eligibility.
Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, Jacobsen N, Ruutu T, de Lima M, Finke J, Frassoni F, Gluckman E; Acute Leukemia Working Party of European Blood and Marrow Transplant Group; Eurocord-Netcord Registry. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004 Nov 25;351(22):2276-85. doi: 10.1056/NEJMoa041469.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Metabolism, Inborn Errors
Metabolic Diseases
Nutritional and Metabolic Diseases
Primary Completion
November 26, 2012
Actual (reported)
Study Completion
November 26, 2012
Actual (reported)
Last Updated
December 21, 2018
Record last verified: 2012-11-26
Source record
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.